Thank you for Subscribing to Life Science Review Weekly Brief
The new advanced technology trends is accelerating patient recruitment that will ultimately minimize long-term disruption.
FREMONT, CA: The influence of Covid-19 on the life sciences industry, like many others, cannot be underestimated. Pharma businesses and clinical research organizations can predict additional disruption as they manage new lockdowns, from postponed enrolment to delayed or abandoned trials.
Patient recruiting is still a top priority. Researchers believe that pharma companies and CROs may adjust trial design and informed recruitment strategies to allow a rapid recovery and, most importantly, deliver novel medications to market faster by using crucial technological initiatives.
An industry in recovery
First, put this in context with some of the characteristics that are influencing industry recovery. There are a few significant obstacles to overcome, particularly in terms of clinical study efficiency. Companies can clear backlogs and start new trials as soon as feasible if they can overcome these obstacles.
Organizations can start with the requirement to recruit patients from smaller, more diversified groups, earlier missed deadlines, and non-starter trials have occurred from failing to enroll the correct patients or even any patients. It's an expense the industry cannot afford at the moment.
Due to the trials for possible Covid-19 vaccines and the necessity to detect patients from specific community profiles, it came to attention. The trials frequently involve vulnerable groups who are the most in danger from Covid-19 exposure. As a result, a second aspect is the requirement to risk score patients as soon as possible.
Trust is, naturally, a significant issue when recruiting new clinical trial participants - more so this year than ever before. Companies understand how important it is to secure individual patient safety to achieve good outcomes and accelerate development projects.
Effective communication is critical in this situation. A consistent, patient-centered approach throughout primary and secondary care will increase patient engagement, develop trust, and ensure that patient recruitment reaches its maximum capabilities.
Innovating recruitment strategies with data
Clinical trials will be transformed by connected AI-enhanced, digital, and virtual technology. This means prioritizing speed, security, effectiveness, and, most importantly, patient-centricity. These criteria are more important than ever as trial sponsors look for methods to save costs and boost productivity. By leveraging the industry's data assets, researchers can further broaden their search for appropriate clinical subjects, breaking free from conventional methods.
Deliver faster patient recruitment with technology
A clinical trial might cost up to $600,000 per day if it is delayed. Increasing the speed of their data-driven approach to trials will revolutionize patient recruitment techniques for trial managers.
Consider the possibilities of electronic health records (EHRs) in this context, mainly supporting research viability. The previously unavailable sources of eligible patients bring up larger and new patient pools, allowing access to existing neglected patient populations. The organization will also have more control over the final patient recruiting process with pre-screening. Utilizing this data resource provides trial managers with a multi-layered understanding of patients, allowing for a more predicted trial outcome while controlling expenditures.